Etiologic classification of orbital tumors causing secondary glaucoma.
Secondary glaucoma due to ocular and orbital tumors can be a diagnostic challenge. It is an essential differential to consider in eyes with a known tumor as well as with unilateral, atypical, asymmetrical, or refractory glaucoma. Various intraocular neoplasms including iris and ciliary body tumors (melanoma, metastasis, lymphoma), choroidal tumors (melanoma, metastasis), vitreo-retinal tumors (retinoblastoma, medulloepithelioma, vitreoretinal lymphoma) and orbital tumors (extra-scleral extension of choroidal melanoma or retinoblastoma, primary orbital tumors) etc. can lead to raised intraocular pressure. The mechanisms for glaucoma include direct (tumor invasion or infiltration related outflow obstruction, trabecular meshwork seeding) or indirect (angle closure from neovascularization or anterior displacement or compression of iris) or elevated episcleral venous pressure secondary to orbital tumors. These forms of glaucoma need unique diagnostic techniques and customized treatment considerations as they often pose therapeutic dilemmas. This chapter will review and discuss the mechanisms, clinical presentations and management of glaucoma related to ocular and orbital tumors.
- ocular tumors
- secondary glaucoma
- orbital tumors
- angle infiltration
- neovascular glaucoma
- neoplastic glaucoma
With the advent of constantly evolving and advancing ophthalmic imaging techniques as well as surgical modalities in the field of ophthalmic diseases, diagnostic accuracy, and treatment outcomes of ocular as well as orbital tumors have improved remarkably over the past few years. Raised intraocular pressure (IOP) is known to be one of the presenting features or associated finding for numerous ocular as well as orbital tumors. Ocular and orbital tumors can cause secondary glaucoma due to various mechanisms. They often pose a diagnostic challenge as well as a therapeutic dilemma owing to the complex pathophysiology involved. A thorough clinical evaluation, appropriate index of suspicion and optimum use of ancillary testing can lead to a proper diagnosis and management in such scenario.
Intraocular tumors that can lead to secondary glaucoma are malignancies like iris melanoma, iris metastasis, iris lymphoma, ciliochoroidal melanoma, retinoblastoma as well as benign pathologies like iris melanocytoma, benign ciliary body medulloepithelioma, diffuse choroidal hemangioma.  Indicators for a possible underlying intraocular tumor are, markedly elevated and often asymmetric level of IOP, acquired iris heterochromia, glaucoma non-responsive to optimum treatment or accompanying distinctive ocular features. [1, 2] The mechanism by which these tumors can cause secondary glaucoma varies with tumor type, size, and extent of the main tumor as well as seeding, tumor location, growth pattern, ongoing treatment along with secondary features related to the tumor.  Iris and predominantly ciliary body tumors located in anterior segment can cause glaucoma by direct infiltration of anterior chamber angle or because of iris neovascularization; while large tumors originating in retina or choroid are likely to cause glaucoma following iris neovascularization because of long standing or total retinal detachment or secondary angle closure. [1, 2]
Orbital tumors which can be congenital, traumatic, inflammatory, vascular, or neoplastic in origin may cause secondary glaucoma due to mass effect or anatomical and vascular changes leading to raised IOP  Orbital tumors causing raised orbital pressure may directly increase the IOP by increasing hydrostatic pressure around the globe or indirectly by raising the episcleral venous pressure.
Management of secondary glaucoma due to ocular and orbital tumors depends on both tumor characteristics and glaucoma related factors. Treatment of primary tumor may lead to IOP control in some cases while for others, management options include medical management, laser trabeculoplasty, transscleral cyclophotocoagulation, anti-VEGF injections, minimally invasive glaucoma surgery (MIGS), filtering or shunting surgery or enucleation. Glaucoma surgery like filtering or shunting procedure can be performed with due caution in proven benign or completely regressed tumors post-treatment. Such surgeries in an eye with suspected but unproven benign/malignant ocular tumor must be avoided to prevent unintended iatrogenic tumor dispersion or seeding especially in cases with iridociliary tumors or retinoblastoma.
2. Mechanisms of glaucoma secondary to ocular and orbital tumors
Solid tumor invasion- related outflow obstruction
Infiltrative tumor -related outflow obstruction
Trabecular meshwork seeding
Angle closure from neovascularization
Angle closure (compressive and rotational)
Ghost cell- Hemolytic
Elevated episcleral venous pressure
3. Ocular tumor related glaucoma
3.1 Anterior segment tumors
Anterior uveal tumors known to cause secondary glaucoma are iris/ciliary body melanocytoma, iris melanoma (nodular or diffuse), ciliary body melanoma (nodular or ring melanoma), iris lymphoma and iris metastasis. Direct invasion of the anterior chamber angle by infiltration followed by neovascularization and trabecular meshwork tumor seeding are the common etiologies of raised IOP in iris tumors; while pigment dispersion followed by direct angle invasion are the common etiologies for same in pigmented ciliary body tumors. [1, 2, 5, 6]
Suspected melanocytoma can be observed cautiously. They are very rarely known to show malignant transformation.  Clear corneal approach fine needle aspiration biopsy, minimally invasive Finger Iridectomy technique (FIT), iridectomy or iridogoniocyclectomy can be utilized to obtain histopathological diagnosis in atypical iris nevi and suspected melanocytoma. [7, 10] Secondary glaucoma demonstrating melanocytoma eyes can be treated medically, by transscleral photocoagulation, by sector iridectomy or with glaucoma filtration surgery. [7, 8, 11, 12] However, a diagnostic confirmation of the lesion by prior biopsy and histopathology is mandated before planning a filtering surgery. Local surgical resection can be used to treat the secondary glaucoma caused by necrotic iris melanocytoma. [8, 13] Enucleation is reserved for painful blind eyes or eyes with absolute glaucoma.
Management of iris and iridociliary melanoma depends upon tumor size, location or extent, tumor seeding and presence of tumor related glaucoma. [15, 20] Local resection (iridectomy, iridocyclectomy), plaque brachytherapy, proton beam radiotherapy and enucleation are available treatment options for both nodular as well as diffuse iris melanoma. [6, 15, 20, 21] Secondary glaucoma in association with iris melanoma can be managed with medications, transscleral photocoagulation or laser trabeculoplasty.  Antivascular endothelial growth factor (anti-VEGF) injections can be tried in neovascular glaucoma.  Cases with refractory glaucoma resulting in blind painful eyes may warrant enucleation.  Filtering, shunting surgery or MIGS should be avoided in eyes with untreated tumor to prevent tumor spread outside of the globe. Diffuse iris melanoma or trabecular meshwork melanoma if misdiagnosed or missed prior to performing above named procedures can warrant enucleation for further tumor control. [3, 19]
Other disorders like: Multiple myeloma, a malignant proliferation of plasma cells characterized by monoclonal production od immunoglobulins; Juvenile Xanthogranuloma, a benign histiocytic skin disorder can also affect anterior segment and lead to raised IOP. 
3.2 Posterior segment tumors
3.2.1 Choroidal tumors
Contrary to traditional thinking, a recent study of analysis of glaucoma drainage device surgery for control of IOP in treated (totally regressed) uveal melanoma (both anterior as well as posterior) did not find a greater risk of local or extraocular recurrence after a median follow up of 2 years.  However, further analysis with larger sample size and longer follow up duration is warranted, and caution needs to be exercised while deciding regarding treatment options for control of IOP in such cases.
3.2.2 Retinal tumors
4. Glaucoma associated with management of ocular tumors
4.1 Special considerations
In instances where patient seeks attention with glaucoma as the presenting feature, a detailed work up involving slit lamp examination, dilated fundus examination, gonioscopy of anterior chamber angle, high frequency ultrasound microscopy (UBM) and ultrasound B scan of posterior segment will provide essential clues about diagnosis of possible intraocular tumor. Initial management with IOP lowering medications should be the first line treatment with simultaneous investigation for underlying cause.  When the tumor presents with atypical features or causes diagnostic uncertainty, a diagnostic biopsy is warranted in managing such case of secondary glaucoma.  Systemic work up with the help of positron emission tomography (PET) CT scan can come in handy while evaluating a case of possible secondary ocular metastasis by highlighting an existing primary malignancy elsewhere.
4.2 Orbital tumor related glaucoma
The orbit is a pyramidal structure limited by bony walls except from anteriorly where it is limited by soft tissue i.e., orbital septum and eyelids. Thus, any instances of increased orbital volume may lead to increased hydrostatic pressure in the orbit. This increased orbital pressure can have a direct effect of IOP by raised hydrostatic pressure around the eye or indirect effect by compression of episcleral and orbital veins raising venous pressure. The episcleral venous system mainly empties into the anterior ciliary and superior ophthalmic veins and eventually draining into cavernous sinus. Thus, any disease process that might affect this drainage pathway due to structural, occlusive, compressive, or destructive pathophysiology can alter and raise IOP causing secondary glaucoma.  Focal mass effect due to tumors or swollen extraocular muscles may directly compress the eye globe leading to raised IOP while, vascular changes affecting venous pressure due to compression of episcleral veins or altered arterio-venous flow may also increase IOP indirectly.
Table 1 summarizes the broad etiological classes of orbital tumors leading to rise in IOP and secondary glaucoma. Open angle glaucoma is more common in the listed diseases however, angle closure along with acute angle closure glaucoma has also been reported in variety of pathologies.
|1||Inflammatory||Non-specific Orbital Inflammatory Disease (NSOID)|
Thyroid eye disease
Orbital granulomatous disease
Orbital Foreign Body granuloma
Juvenile Xanthogranuloma (orbital histiocytosis)
|2||Vascular||Carotid-cavernous fistula (Direct or Indirect)|
Optic nerve glioma
Optic nerve meningioma
Lacrimal gland tumors
Primary orbital melanoma
|4||Secondary||Orbital metastasis (from breast, lung carcinoma)|
Orbital chloroma (Acute myeloid leukemia)
Invasive (secondary) ocular melanoma
Extra-scleral (orbital) extension of retinoblastoma
Invasive (secondary) squamous cell carcinoma
Phakomatosis (Neurocutaneous syndromes)
Collagen tissue disorders (Lupus erythematosus, Wegener granulomatosis)
IOP evaluation should be routinely performed when evaluating a case of suspected orbital tumor or pathology. Gonioscopic examination can provide essential information regarding the status of the anterior chamber angle as well as show evidence of blood in Schlemm’s canal as the distinguishing feature of elevated venous pressure. The treatment of primary orbital pathology along with medical management of raised IOP is indicated for control of orbital tumor related secondary glaucoma.
In sum, glaucoma can be associated with various ocular as well as orbital tumors. It may constitute one of the many manifesting clinical features or be the sole presenting feature of these pathologies. Appropriate diagnosis and timely management of these tumors can help eye and vision salvage; however, a misdiagnosis or delayed diagnosis due to initial presentation as secondary glaucoma can lead to catastrophic sequel necessitating enucleation and can pose a greater risk to life. A thorough clinical evaluation, use of ancillary testing and stepwise management can help achieve optimum visual outcome and overall survival in cases with ocular or orbital tumors.
The author acknowledges contributions from Dr. Paul T Finger MD, FACS, Director- The New York Eye Cancer Center, New York, USA and Dr. Santosh G Honavar MD, FACS, Director- Ocular Oncology Services, Centre For Sight Hospital, Hyderabad, India for select clinical images used in this chapter.
Shields CL, Shields JA, Shields MB, Augsburger JJ. Prevalence and mechanisms of secondary intraocular pressure elevation in eyes with intraocular tumors. Ophthalmology 1987; 94:839-846
Radcliffe NM, Finger PT. Eye cancer related glaucoma: current concepts. Survey of ophthalmology. 2009 Jan 1;54(1):47-73.
Camp DA, Yadav P, Dalvin LA, Shields CL. Glaucoma secondary to intraocular tumors: mechanisms and management. Current Opinion in Ophthalmology. 2019 Mar 1;30(2):71-81.
Nassr MA, Morris CL, Netland PA, Karcioglu ZA. Intraocular pressure change in orbital disease. Survey of ophthalmology. 2009 Sep 1;54(5):519-44.
Foulds WS, Lee WR. The significance of glaucoma in the management of melanomas of the anterior segment. Trans Ophthalmol Soc UK. 1983;103(Pt 1):59—63
Shields CL, Shah SU, Bianciotto CG, Emrich J, Komarnicky L, Shields JA. Iris melanoma management with iodine-125 plaque radiotherapy in 144 patients: impact of melanoma-related glaucoma on outcomes. Ophthalmology. 2013 Jan 1;120(1):55-61.
Demirci H, Mashayekhi A, Shields CL, et al. Iris melanocytoma: clinical features and natural course in 47 cases. Am J Ophthalmol 2005; 139: 468-475.
Fineman MS, Eagle RC Jr, Shields JA, et al. Melanocytomalytic glaucoma in eyes with necrotic iris melanocytoma. Ophthalmology 1998; 105: 492-496.
Cialdini AP, Sahel JA, Jalkh AE, et al. Malignant transformation of an iris melanocytoma. A case report. Graefes Arch Clin Exp Ophthalmol. 1989;227(4):348—5
Finger PT, Latkany P, Kurli M , et alThe Finger iridectomy technique: small incision biopsy of anterior segment tumours British Journal of Ophthalmology2005; 89:946-949.
Fountain TR, Goldberg MF, Green WR. Glaucoma and a melanocytic iris lesion in an-18-year-old. In: Schachat AP, editor. Current practice in ophthalmology. St. Louis: Mosby, 1992:371-380.
Chen MJ, Liu JL, Li WY, et al. Diode laser transscleral cyclophotocoagulation in the treatment of refractory glaucoma with iris melanocytoma. J Chin Med Assoc 2008; 71:546-548.
Shields JA, Annesley WH Jr, Spaeth GL. Necrotic melanocytoma of iris with secondary glaucoma. Am J Ophthalmol 1977;84:826-829.
Shields CL, Shields JA, Materin M, et al. Iris melanoma: risk factors for metastasis in 169 consecutive patients. Ophthalmology. 2001;108:172-178.
Khan S, Finger PT, Yu GP, et al. Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study. Arch Ophthalmol. 2012;130(1): 57-64.
Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011; 118:1881-1885.
Demirci H, Shields CL, Shields JA, et al. Ring melanoma of the anterior chamber angle: a report of fourteen cases. Am J Ophthalmol 2001; 132:336-342.
Van Buskirk EM, Leure-duPree AE. Pathophysiology and electron microscopy of melanomalytic glaucoma. Am J Ophthalmol. 1987;85(2):160—6
Demirci H, Shields CL, Shields JA, et al. Diffuse iris melanoma: a report of 25 cases. Ophthalmology 2002; 109:1553-1560.
Shields CL, Kaliki S, Furuta M, et al. Iris melanoma features and prognosis in children and adults in 317 patients. J Am Assoc Pediatr Ophthalmol Strabismus 2012;16:10-6.
Chaugule SS, Finger PT. Regression patterns of iris melanoma after palladium-103 (103Pd) plaque brachytherapy. Ophthalmology. 2017 Jul 1;124(7):1023-30.
Girkin CA, Goldberg I, Mansberger SL, et al. Management of iris melanoma with secondary glaucoma. J Glaucoma 2002; 11:71-74.
Bianciotto C, Shields CL, Kang B, Shields JA. Treatment of iris melanoma and secondary neovascular glaucoma using bevacizumab and plaque radiotherapy. Arch Ophthalmol 2008; 126:578-579.
Shields JA, Shields CL, Shields MB. Glaucoma associated with intraocular tumors. In: Ritch R, Shields MB, Krupin T, editors. The glaucomas, 2nd ed. St. Louis, MO: Mosby; 1996. pp. 1131-1139.
Demirci H, Shields CL, Shields JA, Honavar SG, Eagle RC Jr: Ring melanoma of the ciliary body: report on twenty-three patients. Retina 2002;22:698-706; quiz 852-853
Gunduz K, Shields CL, Shields JA, et al. Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement. Arch Ophthalmol 1999;117:170-177
Zhao M, Mu Y, Dang Y, Zhu Y. Secondary glaucoma as initial manifestation of ring melanoma: a case report and review of the literature. Int J Clin Exp Pathol 2014; 7:8163-8169.
Lee V, Cree IA, Hungerford JL. Ring melanoma—a rare cause of refractory glaucoma. Br J Ophthalmol 1999; 83:194-198.
Kaliki S, Eagle RC, Grossniklaus H, et al. Inadvertent implantation of aqueous tube shunts in glaucomatous eyes with unrecognized intraocular neoplasms: report of 5 cases. JAMA Ophthalmol 2013; 131:925-928.
Gragoudas ES, Lane AM, Munzenrider J, Egan KM, Li W: Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. Trans Am Ophthalmol Soc 2002; 100: 43-48; discussion 48-49.
Pasternak S, Erwenne CM, Nicolela MT: Subconjunctival spread of ciliary body melanoma after glaucoma filtering surgery: a clinicopathological case report. Can J Ophthalmol 2005; 40: 69-71
Shields CL, Welch RJ, Malik K, et al. Uveal metastasis: clinical features and survival outcomes of 2214 tumors in 1111 patients based on primary tumor origin. Middle East Afr J Ophthalmol 2018; 25:81-90.
Shields CL, Kaliki S, Crabtree GS, et al. Iris metastasis from systemic cancer in 104 patients: the 2014 Jerry A. Shields Lecture. Cornea 2015; 34:42-48.
Seidman CJ, Finger PT, Silverman JS, Oratz R. Intravitreal bevacizumab in the management of breast cancer iris metastasis. Retin Cases Brief Rep 2017; 11:47-50
Aydin A, Tezel TH. Use of intravitreal bevacizumab for the treatment of secondary glaucoma caused by metastatic iris tumor. J Glaucoma 2018; 27:e113–e116.
Chan CC, Buggage RR, Nussenblatt RB. Intraocular lymphoma. Curr Opin Ophthalmol. 2002;13(6):411—8
Gauthier AC, Nguyen A, Munday WR, et al. Anterior chamber non-Hodgkin lymphoma of the iris masquerading as uveitis-glaucoma-hyphema syndrome. Ocul Oncol Pathol 2016; 2:230-233
Bawankar P, Das D, Bhattacharjee H, et al. Systemic diffuse large B-cell lymphoma masquerading as neovascular glaucoma. Indian J Ophthalmol 2018; 66:317-319.
Matano S, Ohta T, Nakamura S, et al. Leukemic hypopyon in acute myelogenous leukemia. Ann Hematol. 2000;79(8): 455—8
Othman IS, Assem M, Zaki IM. Secondary glaucoma as initial manifestation of uveal melanoma. Saudi Journal of Ophthalmology. 2013 Jul 1;27(3):203-8.
Vempuluru VS, Jakati S, Krishnamurthy R, Senthil S, Kaliki S. Glaucoma as the presenting sign of intraocular tumors: beware of the masquerading sign. International ophthalmology. 2020 Mar 20:1-7.
Fatehi N, McCannel T, A, Giaconi J, Caprioli J, Law S, K, Nouri-Mahdavi K: Outcomes of Glaucoma Drainage Device Surgery in Eyes with Treated Uveal Melanoma. Ocul Oncol Pathol 2019;5:20-27. doi: 10.1159/000488056
Shields CL, Honavar SG, Shields JA, et al. Circumscribed choroidal hemangioma: clinical manifestations and factors predictive of visual outcome in 200 cases. Ophthalmology 2001; 108:2237-2248.
Finger PT. Radiation therapy for exudative choroidal hemangioma. Indian journal of ophthalmology. 2019 May;67(5):579.
Sen M, Honavar SG. Circumscribed choroidal hemangioma: An overview of clinical manifestation, diagnosis and management. Indian journal of ophthalmology. 2019 Dec;67(12):1965.
Kivela T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol 2009; 93:1129-1131.
Kvanta A, Steen B, Seregard S. Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp Eye Res. 1996;63(5): 511—8
Shields CL, Shields JA, Baez K, et al: Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors. Cancer 73:692-8, 1994
Kaliki S, Srinivasan V, Gupta A, Mishra DK, Naik MN. Clinical features predictive of high-risk retinoblastoma in 403 Asian Indian patients: a case-control study. Ophthalmology. 2015 Jun 1;122(6):1165-72.
Sivak-Callcott JA, O’Day DM, Gass JD, et al. Evidence-based recommendations for the diagnosis and treatment of NVG. Ophthalmology 2001;108:1767-1776
Kim EA, Salazar D, McCannel CA, Kamrava M, Demanes DJ, Lamb J, Caprioli J, McCannel TA. Glaucoma After Iodine-125 Brachytherapy for Uveal Melanoma: Incidence and Risk Factors. Journal of glaucoma. 2020 Jan 8;29(1):1-0.
Finger PT. Plaque radiation therapy for malignant melanomaof the iris and ciliary body. Am J Ophthalmol. 2001; 132(3):328—35
Finger PT. Radiation therapy for choroidal melanoma. Surv Ophthalmol. 1997;42(3):215—32
Mishra KK, Daftari IK, Weinberg V, Cole T, Quivey JM, Castro JR, Phillips TL, Char DH. Risk factors for neovascular glaucoma after proton beam therapy of uveal melanoma: a detailed analysis of tumor and dose–volume parameters. International Journal of Radiation Oncology* Biology* Physics. 2013 Oct 1;87(2):330-6.
Gombos D.S. (2019) Localised Therapy and Biopsies of Intraocular Tumors. In: Chaugule S., Honavar S., Finger P. (eds) Surgical Ophthalmic Oncology. Springer, Cham.